Need professional-grade analysis? Visit stockanalysis.com
$2.44B
17.29
5,784
1.98%
Carl Zeiss Meditec AG (AFX) trades on XETRA (Frankfurt) in EUR. The company is classified in the Healthcare sector under the Medical Instruments & Supplies industry. The stock currently trades at EUR27.90, up 0.22% from the previous close.
Over the past year, AFX has traded between a low of EUR23.54 and a high of EUR65.90. The stock has lost 52.9% over this period. It is currently 57.7% below its 52-week high.
Carl Zeiss Meditec AG has a market capitalization of $2.44B, with a price-to-earnings ratio of 17.29 and a dividend yield of 1.98%.
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
Side-by-side comparison against top Healthcare peers.